Background
==========

The autosomal recessive disorder Fanconi anemia (FA) is clinically characterized by bone marrow failure, predisposition to cancer and various developmental abnormalities \[[@B1]\]. FA is genetically heterogeneous, and thus far eight complementation groups have been described. Six of the identified FA genes (*FANCA*, -*C*, -*D2*, -*E*, -*F*, and -*G*; \[[@B2]-[@B8]\]) encode proteins that are unique and lack apparent homology to other proteins or to each other. In addition, there are no conserved motifs present in these FA proteins, hampering understanding of their molecular function. Recently, biallelic mutations were found in the *BRCA2*gene in patients belonging to complementation groups FA-D1 and one FA-B patient \[[@B9]\]. At the cellular level, FA is characterized by increased spontaneous genomic instability and hypersensitivity to DNA crosslinking agents, e.g. cisplatin and mitomycin C (MMC) \[reviewed in \[[@B1]\]\]. Multiple studies have also shown defects in FA cells related to the interferon-signaling pathway. Compared to control cells, FA cells express constitutively high levels of ISGF3 gamma, IRF-1, p21^*waf*1/*Cip*1^and MxA \[[@B10],[@B11]\].

Studies on the FA proteins have shown that five FA proteins, FANCA, FANCC, FANCE, FANCF, and FANCG, bind to each other to form a nuclear core complex \[Reviewed in \[[@B12]\] and \[[@B13]\]\]. FANCD2 is a nuclear protein that requires activation by mono-ubiquitination. In mutant FA cells that lack one of the FA core complex proteins, FANCD2 is not activated by ubiquitination, suggesting that these FA proteins exert a common molecular function in the nuclear compartment of the cell \[[@B14]\]. Whether BRCA2 is involved in the same pathway or exerts a separate function is currently unknown \[[@B15]\].

Crosslinking agents are widely used for the treatment of various types of cancer and are thought to exert their cytotoxic effect predominantly through irreversible binding with DNA. How the FA proteins are related to this cytotoxic effect, e.g. by functioning in processes such as DNA repair, cell cycle control or protection, is unknown. Upon treatment with a discriminating dose of crosslinking agent that will only transiently arrest the growth of wild type cells, FA cells arrest in the late S or early G2-phase of the cell cycle, and ultimately undergo cell death \[[@B16]-[@B21]\]. In contrast to normal cells, FA cells fail to inhibit replicative DNA synthesis after treatment with crosslinking agents. While normal cells will arrest in S-phase, FA cells continue replication and subsequently arrest at a later cell cycle check point \[[@B22],[@B23]\]. This hypersensitivity to crosslinking agents is the hallmark of the FA phenotype.

Many studies have indicated that *in vitro*treatment of cells with cisplatin affects the expression of specific genes involved in various molecular processes such as transcription, DNA repair, apoptosis, and cell cycle regulation. Examples are induction of c-jun, c-fos, ercc1, gadd45, gadd153, and p21^*waf*1/*Cip*1^\[[@B24]-[@B28]\]. Some of these genes respond within hours after treatment of cells, e.g. c-jun, whereas others show maximum changes in expression after 24 to 72 hours, e.g. p21^*waf*1/*Cip*1^, gadd45 and gadd153.

Recently developed techniques, cDNA microarrays and oligonucleotide expression probe arrays, enable the systematic analysis of expression of thousands of genes in a single experiment \[reviewed in \[[@B29]\]\]. These techniques are useful to evaluate possible differences in gene expression profiles between FA and control cells, either at baseline or after crosslinker treatment. To study this, there are a number of experimental approaches to consider. For example, one might compare FA cells with cells from healthy controls. This might necessitate studying a large number of both types of cells in order to reduce false positives due to genetic differences in the cell lines that are unrelated to FA. Another approach would be to study cell lines derived from FA patients that are compared with the same cell lines corrected by transfection with the complementing cDNA. The use of such isogenic cell lines would presumably reduce the number of false positives and therefore reduce the number of cell lines that need to be studied. However, this might also result in a non-physiologic expression of the FA protein in transfected cells, which might influence the expression profiles. Therefore, we used the latter approach in combination with a unique cell line couple, one FA-like cell line and one wild-type, which are both derived from the same (mosaic) patient \[[@B30]\]. This cell line couple has the advantage of being both isogenic and expressing physiologic levels of the FA gene.

The aim of this study was to compare the expression profiles of FA cells defective in one of the FA core complex proteins with isogenic control cells at baseline, as well as in response to treatment with discriminating concentrations of crosslinking agents. Differences in expression profiles of known genes might shed light on the cellular function of the FA proteins.

Methods
=======

Cell lines and cell culture
---------------------------

Lymphoblastoid cell lines that were used in this study are derived from three individuals, one FA-A (HSC72) and two FA-C (HSC536 and VU450) patients. The isogenic control cell lines included an *in vivo*revertant cell line derived from a mosaic patient, VU450R and the non-reverted cell line VU450, or were derived by transfecting the cells with either empty vector or with vectors expressing the complementing cDNAs, HSC72 with pDR2 or pDR2-FANCA-flag \[[@B31]\] and HSC536 with pDR2 or pDR2-flag-FANCC \[[@B17]\]. The VU450R cell line is an ideal isogenic control, since reversion by recombination resulted in endogenous wild-type FANCC expression \[[@B30]\]. Cells were cultured at 37°C in 5% CO~2~in RPMI1640 medium (Life Technologies, Gaithersburg, MD) containing 10% newborn calf serum (Hyclone Laboratories, Lorgan, UT) and supplemented with 200 μg/ml hygromycin for transfected cells.

Cisplatin treatment
-------------------

Optimal discriminating doses of cisplatin (Pharmachemie b.v., NL) for each cell couple were determined using growth inhibition tests \[[@B32],[@B33]\]. Cells were pulse treated for 1 hour with different concentrations (0, 0.2, 0.5, 1, 2, 5, 10, 20, and 50 μM) of cisplatin. Cells were subsequently washed and allowed to grow further until three cell divisions were reached in the untreated samples. For further analysis, concentration of cisplatin was such that the highest differential effect between the FA and control cells was obtained, i.e. growth inhibition of \>50% in FA cells and \<10% in control cells: for the VU450 cell couple, 2.5 μM; HSC536 cell couple, 1 μM; and HSC72 cell couple, 5 μM. Approximately 10^8^cells were pulse treated with cisplatin for one hour, washed and cultured further in separate portions of 2.5 × 10^7^cells in fresh medium.

RNA isolation
-------------

Cells were harvested at various time points after treatment. Total RNA was extracted using TRIzol LS reagent (Life Technologies, Gaithersburg, MD) followed by a second round of RNA purification using RNAeasy columns (QIAGEN, Valencia, CA). Gene expression profiles were determined from the three cell couples without treatment, from the HSC72 cell couple 1, 3, 7 and 24 hours after cisplatin treatment, and from the VU450 cell couple 1 and 7 hours after treatment.

Genechip expression analysis
----------------------------

Gene expression profiles were determined using the Human Genome U95A probe arrays (Affymetrix, Santa Clara, CA) according to the manufacturer\'s protocol. These genechips are oligonucleotide-based and represent \~12,000 human sequences that were previously characterized in terms of function or disease association. Double stranded cDNA was synthesized from each total RNA sample (10 μg) using T7-(dT)24 primer (GENSET Corp) and SuperScript Choice system (Life Technologies, Rockville, MD). From these cDNA samples, target samples were prepared using *in vitro*cRNA transcription with biotinylated nucleoside triphosphates and BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY). The cRNA samples were fragmented and hybridized to U95A probe arrays. Scanning of the arrays was performed with the HP Gene Array Scanner and data quantified using Genechip Analysis Suite 3.3 (Affymetrix, Santa Clara, CA).

Data analysis
-------------

For analysis of the data, the data from all untreated cell couples were combined and used as baseline for normalization. All data sets were subsequently calculated relative to the normalized data. Expression levels of beta-actin and GAPDH (relative intensity) ranged between 0.8 -- 1.2 in all data sets. Genechip Analysis Suite 3.3 (Affymetrix, Santa Clara, CA) and GeneSpring 3.2.2 software (Silicon Genetics, Redwood, CA) was used for analysis of the data. A gene was considered as being up- or down-regulated only if the average difference (AD) was \> 10 (with target intensity for scaling = 100) and if gene was called present. Genes considered of potential interest were: genes \>2-fold up- or down-regulated in all pairs for non-treated samples when comparing FA *v*control, and \>3-fold up- or down-regulated at any time point after cisplatin treatment in either cell couple. A further selection from the latter set of genes was made by scrutinizing for consistency in changes of expression among cell line couples and in response to cisplatin treatment (as indicated in table [2](#T2){ref-type="table"}).

Immunoblotting
--------------

Protein extracts were prepared from cells as described previously \[[@B34]\]. Protein concentration in the extracts was determined using a Bio-Rad Protein Assay (Hercules, CA), and 10 μg protein was loaded on SDS-polyacrylamide gels. Gels were transferred to Immobilon-P membrane (MILLIPORE, Bedford, MA) and blocked in TBST with either 5% dry milk or 5% BSA for 1 hour at room temperature. Incubation with primary antibody was according to the manufacturer\'s protocols. The following primary antibodies were used for immunoblotting: mouse anti-p300 (NM-11) and rabbit anti-p21^*waf*1/*Cip*1^(Zymed Laboratories, San Francisco, CA), mouse anti-CDC25a (abcam, UK), mouse anti-PMS2 (E-19), rabbit anti-RGS2, rabbit anti-BAF170 (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-p16 (G175-405; PharMingen), and mouse anti-β-tubulin (Boehringer Mannheim).

Results
=======

Expression analysis of untreated cells
--------------------------------------

Expression data from three different cell line couples, FA cell lines (HSC72, HS536, and VU450) and their isogenic controls (HSC72 + FANCA, HSC536 + FANCC, and VU450 revertant), were analyzed. In addition, for two cell line couples (HSC72 and VU450), expression profiles were determined after treatment with discriminating concentrations of cisplatin. In general, approximately half of the genes present on the probe arrays were identified as being expressed in the lymphoblastoid cell lines. Some low abundant mRNAs were not detected, as evidenced by the fact that of the four FA genes present on the arrays (FANCA, FANCC, FANCD2 and FANCG), only one (FANCG) was detected, in both FA and control cell lines.

As shown in Table [1](#T1){ref-type="table"}, comparison of the expression profiles from the three FA cell lines and their isogenic controls showed that 10 genes were identified as being more than 2-fold differentially expressed in all cell couples. Although we can not exclude that some of these genes may have a physiological effect, many of the genes in Table [1](#T1){ref-type="table"} are difficult to relate to the molecular defect in FA cells, i.e. genomic instability and cross linker sensitivity. There is still a reasonable chance that the majority of these genes were obtained by chance since only three cell line couples were used. Therefore, we further analyzed those most likely to be related to the FA phenotype, i.e. p300 and p16 that are involved in cell cycle regulation. However, comparison of protein expression by Western blotting showed no consistent differences in either p16 or p300 protein levels (Figure [1](#F1){ref-type="fig"}).

![**p16 and p300 protein expression in FA and control cell lysates.**10 μg protein from indicated cell extracts were immunoblotted with p16, β-tubulin, and p300 specific antibodies, as indicated. Extracts were from HSC536 stably transfected with empty vector (p; lanes 1) or with vector expressing *FANCC*(C; lanes 2), and from HSC72 stably transfected with vector expressing *FANCA*(A; lanes 3) or with empty vector (p; lanes 4). β-tubulin was used as additional loading control.](1471-2326-2-5-1){#F1}

###### 

Differentially expressed genes in untreated FA cells.

  Description                                    GenBank accession no.   Fold change              
  ---------------------------------------------- ----------------------- ------------- ---------- ---------
  *Up regulated in FA cells*                                             *VU450*       *HSC536*   *HSC72*
  \- GLUT1 C-terminal binding protein, GIPC      AF089816                5             2          17
  \- homeo box B7, HOXB7                         M16937                  5             61         3
  \- plasma glutamate carboxypeptidase, PGCP     W29330                  5             3          2
  \- proteinase inhibitor, SERPINB7              U71364                  7             2          6
  \- E1A binding protein p300, EP300             U01877                  2             2          2
  *Down regulated in FA cells*                                                                    
  \- selectin L, SELL                            M25280                  2             16         5
  \- small inducible cytokine A4, SCYA4          J04130                  2             3          41
  \- TXK tyrosine kinase, TXK                    L27071                  10            3          3
  \- solute carrier family 16, SCL16A5           U59299                  2             2          2
  \- cyclin-dependent kinase inhibitor 2A, p16   U26727                  2             203        5

Expression analysis of cisplatin-treated cells
----------------------------------------------

To test the possibility that the hypersensitivity of FA cells to crosslinking agents is reflected by a differential response at the level of gene expression, we first determined the concentration of cisplatin that best discriminated between the FA and control cell line couples. These concentrations were 2.5 μM and 5 μM cisplatin for the VU450 and HSC72 cell couples, respectively (Figure [2](#F2){ref-type="fig"} and data not shown).

![**Cisplatin induced growth inhibition.**VU450 cell lines were one hour pulse treated with indicated concentrations of cisplatin. Dotted line indicates the dosage used for gene expression experiments. VU450R; reverted (crosslinker resistant) cell line and VU450; FA (crosslinker sensitive) cell line.](1471-2326-2-5-2){#F2}

Using specific criteria for differences in response (see methods section), analysis of the expression profiles from untreated versus 1 and 7 hours after cisplatin treatment for the VU450 cell couple and from untreated versus 1, 3, 7, and 24 hours after treatment for the HSC72 cell couple, resulted in 59 genes that were initially identified (Table [2](#T2){ref-type="table"}). The selection criteria were mild, in order to avoid loss of interesting data, thus increasing the risk of identifying genes by chance. This is reflected by the facts that many genes do not show a clear pattern of response to cisplatin treatment and that all genes are in the low intensity range. However, some of the genes in Table [2](#T2){ref-type="table"} are of possible interest in the context of FA and crosslinker treatment, particularly those involved in cell cycle regulation (cdc25A and RGS2), DNA repair (PMS2), and chromatin structure (BAF170). Unfortunately, protein expression analysis using Western blotting did not confirm any consistent changes in protein expression after cisplatin treatment (Figure [3A](#F3){ref-type="fig"}).

![**Protein expression in FA and control cells treated with cisplatin.**10 μg protein from indicated cell extracts were immunoblotted with specific antibodies directed against indicated proteins; A) BAF170, CDC25a, PMS2, RGS2 and β-tubulin; B) p21^*waf*1/*Cip*1^. Extracts were from HSC72 and HSC536 cells transfected with empty vector or with vector expressing correcting cDNA as indicated. Cells were one hour pulse treated with discriminating concentrations of cisplatin; HSC72 with 5 μM and HSC536 with 1 μM. β-tubulin was used as additional loading control.](1471-2326-2-5-3){#F3}

###### 

Differentially expressed genes between FA and control cells after cisplatin treatment.

  Gene Description                                                  GenBank accession no.   Change\*
  ----------------------------------------------------------------- ----------------------- ------------------
  ***Membrane protein***                                                                    
  C-type lectin, AICL                                               X96719                  Up 1 h in WT
  Integral membrane protein, LIG-1                                  W25875                  Up 1 h in FA
  Integral membrane protein, SIGMAR1                                U79528                  NC
  ***Growth factor***                                                                       
  Insulin growth factor binding protein 2, IGFBP-2                  S37730                  NC
  Endothelial cell growth factor, platelet-derived, ECGF1           M63193                  Down 24 h in WT
  IL18R1/IL-1RRP                                                    U43672                  NC
  BMP-4                                                             U43842                  Down 1 h in FA
  IL10R                                                             U00672                  NC
  Notch ligand, JAGL1                                               AF003837                NC
  ***Signal transduction***                                                                 
  Adapter molecule in signal transduction, DOC1                     U53445                  Up 24 h in FA
  SRC family tyrosine kinase, FYN                                   M14333                  Down 24 h in FA
  Protein tyrosine phosphatase, PTPG                                U46116                  Down \>7 h in FA
  Regulator of G-protein signaling, G0S8/RGS                        L13463                  Up 1 h in FA
  Regulator of G-protein signaling, GIPC/RGS19IP1                   AF089816                Up 24 h in WT
  Mitogen-activated protein kinase kinase kinase kinase 4, MAP4K4   AB014587                NC
  Serine/threonine kinase, KIAA0623                                 AB014523                NC
  Related to the N-terminus of TRE, RNTRE                           D13644                  NC
  Related to intracellular calcium signaling, HOMER-1B              Y17829                  NC
  MEK6/MKK6                                                         U39657                  NC
  Zinc finger protein, LOC58500                                     X16282                  NC
  LYT10/NF-kB2                                                      U20816                  NC
  Dual specific tyrosine kinase, DYRK2                              Y13493                  NC
  Phospholipase C beta 2, PLCB2                                     M95678                  NC
  Containing Pleckstrin homology domain, KIAA0763                   AB18306                 NC
  Vesicular Rab-GAP/TBC-containing protein, AD3                     AB024057                NC
  Calcium-binding protein, S100C/Calgizzarin                        D38583                  NC
  ***Transcription factor***                                                                
  Transcript homolog, MEST/PEG1                                     D78611                  NC
  Myotubularin related protein 2, MTMR2                             AB028996                NC
  Homeobox protein related to skeletal development, MSX1            M97676                  NC
  Transcription factor, MRG1                                        U65093                  NC
  Homeobox, PRH/PRHX                                                L16499                  NC
  MSX2/MSH/HOX8                                                     D89377                  NC
  Transcriptin activating factor, CREBP                             L05515                  NC
  Transcription coactivator, TCFEC/TFECL                            D43945                  NC
  Putative transcription regulator, CARM-1                          AI660225                Down 7 h in FA
  ***Cell cycle***                                                                          
  CDC25A                                                            M81933                  NC
  ***Apoptosis***                                                                           
  Similar to rat CIPHAR-1, DKFZp564O0823                            AL080121                NC
  BCLX                                                              Z23115                  NC
  Protease inhibitor, PLANH2/PAI2                                   Y00630                  NC
  Vanin-2, VNN2                                                     D89974                  Down 24 h in WT
  ***DNA repair/Chromosome regulator***                                                     
  Similar to DNA helicase, FLJ10738                                 W28620                  NC
  HPARG                                                             AF005043                NC
  BAF170                                                            U66616                  NC
  PMS2                                                              U13696                  NC
  ***Intracellular processing***                                                            
  Ubiquitin protein ligase, E6-AP                                   AF002224                Up \>1 h in WT
  Putative splicing factor, DOM3Z                                   AF059252                Down \>7 h in FA
  CBP2/TAFI                                                         M75106                  NC
  Uronyl 2-sufotransferase                                          AB020316                NC
  ***Miscellaneous***                                                                       
  Procollagen-proline, 2-oxoglutarate 4-dioxygenase, P4HA2          U90441                  NC
  Unknown, FLJ21174                                                 AA149307                NC
  Unknown, expressed in macrophage                                  X89059                  Up \>1 h FA
  Clathrin light chain b                                            X81637                  NC
  Related to lipodystrophy, LPIN2                                   D87436                  NC
  ME1                                                               U43944                  NC
  Unknown, KIAA0090                                                 D42044                  Down 24 h in WT
  Unknown, DKFZp564I122                                             AL080062                NC
  Unknown, KIAA0241                                                 D87682                  NC

\* NC indicates that the observed changes were not consistent. When consistent changes were observed indicated are up or down regulation, followed by time point(s) after treatment at which changes of expression were observed, and cell type; WT indicates observed in corrected cells, FA indicates observed in FA cells.

Of the genes with relatively high signal intensities, the cell cycle inhibitor p21^*waf*1/*Cip*1^was increased in FA cells (HSC72) 24 hours after treatment but not in control cells (HSC72 + FANCA). However, this increase was \< 2-fold and therefore excluded in the initial analysis. Western blot analysis of p21^*waf*1/*Cip*1^protein expression showed a strong increase in FA cells at 24 hours after cisplatin treatment, while p21^*waf*1/*Cip*1^was only slightly increased in the corrected cells (Figure [3B](#F3){ref-type="fig"}). In addition, p21^*waf*1/*Cip*1^appeared to be somewhat higher expressed in FA cells even without treatment, which was not observed in the expression array analysis.

Discussion
==========

The FA proteins have a caretaker function and a defective FA pathway results in chromosomal instability, a phenotype that is aggravated by exposure of cells to cross-linking agents \[[@B1]\]. Here we have tried to identify differences in gene expression between FA and control cells that might shed light on the molecular role of the FA proteins. Although recent findings of BRCA2 mutations in a subset of FA patients and studies on the FANCD2 protein suggests a link between the FA pathway, BRCA1, and DNA repair \[[@B9],[@B14]\], the exact function of the FA core complex remains elusive.

We examined samples using oligonucleotide arrays harboring probes directed to approximately 12,000 different transcripts. Various types of crosslinking agents are used in FA research, such as mitomycin C, diepoxybutane, psoralen with UV, and cisplatin \[[@B1]\]. In the present study, we used cisplatin because the effect of this agent on gene expression has been well described and there is no need for metabolic activation of the drug (unlike mitomycin C). Relatively late effects, such as cell cycle arrest and apoptosis, have been documented for FA \[[@B16]-[@B23]\]. Our main interest, however, was to determine the effect on early response genes that preceded cell cycle arrest. Therefore, cells were pulse treated for one hour with cisplatin and samples taken shortly thereafter. The concentration of cisplatin used was chosen to achieve the highest discrimination between FA and control cells in growth inhibition assays. Although this cytotoxic dosage is relatively low compared to those used in prior studies of cisplatin-induced gene expression changes, we reasoned that a higher dosage would lead to indiscriminate growth inhibition in both FA and control cells \[[@B17],[@B18],[@B20]\]. In addition, these concentrations were found to be sufficient for inactivating tyrosine phosphorylation of CDC2, 24 hours post treatment, as assessed by Western blotting (data not shown).

The profiling analysis revealed differences in expression of a number of genes, many of which are difficult to relate to the FA pathway or are unlikely to be expressed in B-lymphocytes. Only a few genes are related to processes that are possibly linked to the FA defect, such as those involved in cell cycle regulation, chromatin structure, and DNA mismatch repair. However, using Western blot analysis with antibodies directed to the respective gene products, we were unable to confirm differences in protein levels for all these genes. Genes that previously have been shown to respond to cisplatin and that were present on the arrays, i.e. c-jun, c-fos, ercc1, gadd153, gadd45, pcna and p21^*waf*1/*Cip*1^, were not changed under the conditions used, except for an increase in expression of p21^*waf*1/*Cip*1^. Although the change in our experiments was \< 2-fold, there was a clear induction of p21^*waf*1/*Cip*1^expression in FA cells 24 hours post treatment that was not seen in the control cells. Microarray based experiments to discover cisplatin induced differences in gene expression have been performed previously both using cell lines \[[@B35]\] and tissues from rats \[[@B36]\]. These experiments are however difficult to relate to our experiment due to much longer exposure time to similar concentrations of cisplatin used \[[@B35]\] or due to the differences in experimental approach \[[@B36]\]. Although in those experiments many genes were found to be differentially expressed, also p21^*waf*1/*Cip*1^was found to be induced by cisplatin treatment. The reason for not detecting other cisplatin-induced genes in our experiments might be the relatively low concentrations of cisplatin used. This suggests that p21^*waf*1/*Cip*1^(compared to other genes) regulation is very sensitive to cisplatin, at least in lymphoblastoid FA cells. p21^*waf*1/*Cip*1^is known to be a key regulator of G1 cell cycle arrest, but has more recently also been implicated in G2 cell cycle regulation \[[@B37]\]. This observation fits well with the previously observed upregulation of p53 and cyclin B proteins, inactivation of CDC2, and cell cycle arrest that follows exposure to low doses of cross-linking agents \[[@B17]-[@B19]\].

Earlier studies reported that FA lymphoblasts express increased levels of transcripts from genes connected to the interferon pathway, IRF-1 and MxA \[[@B10],[@B11]\]. Although the approaches used were different, these observations are not confirmed by our data. Both genes were detected as being expressed but showed no significant differences between FA and controls. In addition, the constitutive elevated expression of p21^*waf*1/*Cip*1^observed in FA cells \[[@B9]\] was not found at the level of mRNA in our experiments. However, we did observe a slight increased expression of p21^*waf*1/*Cip*1^protein in FA cells. This might be explained by posttranscriptional regulation of p21^*waf*1/*Cip*1^or by a relatively low sensitivity of the expression arrays, incapable of detecting minor increases in mRNA. Interestingly, the observed elevated levels of p21^*waf*1/*Cip*1^expression in FA cells is reminiscent of a number of other DNA repair defective cell types, i.e. those defective in ATM, ERCC1, BRCA1, and BRCA2 \[[@B38]-[@B42]\].

Except for p21^*waf*1/*Cip*1^, these experiments did not reveal differences in gene expression that could explain the basic defect in FA, when looking at baseline or when looking for genes that preceded cisplatin-induced cell cycle changes. There are several possible explanations possible for this. First, no significant changes at the transcriptional level are present in FA cells. It might well be that phenotypic differences of FA cells are predominantly reflected at the posttranslational level. The recent finding of FANCD2 mono-ubiquitination suggests that regulation by protein modification is an important step in the FA pathway \[[@B14]\]. Second, subtle changes in gene expression might remain undetected. The up- or down-regulation of an entire functional pathway may have large effects but be difficult to trace using these types of experiments, particularly when our knowledge of components involved in the various functional pathways is limited. Third, expression of certain genes may be different but not detected either because of lack of sensitivity or absence of the oligonucleotide sequence for those specific genes in the arrays used. Concerning sensitivity, it might be that the response of cells to cross-linker damage is related to signals at a certain stage of the cell cycle (e.g. during replication), resulting in a dilution of the response when using an asynchronous population of cells. The p21^*waf*1/*Cip*1^results showed that differences in expression of transcripts with high intensity on the arrays were detected even though this was a single data point and the difference was \< 2-fold. Therefore, differences \< 2-fold in genes with low intensity signals are presumably present but missed because of the increasing levels of noise in that region of intensity, making it difficult to discriminate between true and false positives in a limited number of samples.

Conclusions
===========

Analysis of the expression data resulted in the identification of 10 genes (Table [1](#T1){ref-type="table"}) that were found to be consistently differentially expressed between FA and control cells, as well as 59 genes (Table [2](#T2){ref-type="table"}) that exhibited different response patterns between FA and control cells after treatment with cisplatin. However, subsequent analysis of selected genes at the protein level by Western blot analysis did not confirm the observed differences in expression. Several limitations of the experimental approach were discussed that might explain these results.

The observed strong cisplatin-induction of p21^*waf*1/*Cip*1^in FA cells, but not in control cells, suggests that FA cells respond similarly as non-FA cells but in a hypersensitive manner. According to experiments from other investigators \[[@B20]\] cell cycle checkpoints function properly, suggesting that cross-linking agents evoke more damage or create damage that remains unrepaired in cells with a defective FA pathway. Therefore, the observed increase in basal p21^*waf*1/*Cip*1^levels in FA cells by Western blot analysis most likely reflects a physiologic response to the presence of spontaneous damage in a subpopulation of these cells.
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